Healthcare Capital Partners... Net Worth

The estimated Net Worth of Healthcare Capital Partners... is at least $10.2 millió dollars as of 14 August 2020. Healthcare Partners owns over 451,000 units of Unum Therapeutics stock worth over $10,234,892 and over the last 4 years Healthcare sold UMRX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Healthcare Partners UMRX stock SEC Form 4 insiders trading

Healthcare has made over 1 trades of the Unum Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Healthcare bought 451,000 units of UMRX stock worth $1,136,520 on 14 August 2020.

The largest trade Healthcare's ever made was buying 451,000 units of Unum Therapeutics stock on 14 August 2020 worth over $1,136,520. On average, Healthcare trades about 451,000 units every 0 days since 2020. As of 14 August 2020 Healthcare still owns at least 4,355,273 units of Unum Therapeutics stock.

You can see the complete history of Healthcare Partners stock trades at the bottom of the page.

Insiders trading at Unum Therapeutics

Over the last 7 years, insiders at Unum Therapeutics have traded over $0 worth of Unum Therapeutics stock and bought 1,283,156 units worth $11,122,392 . The most active insiders traders include Llc Fmr, Liam Ratcliffe és Bruce Booth. On average, Unum Therapeutics executives and independent directors trade stock every 72 days with the average trade being worth of $286,216. The most recent stock trade was executed by Healthcare Capital Partners... on 14 August 2020, trading 451,000 units of UMRX stock currently worth $1,136,520.

What does Unum Therapeutics do?

Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Complete history of Healthcare Partners stock trades at Unum Therapeutics

Unum Therapeutics executives and stock owners

Unum Therapeutics executives and other stock owners filed with the SEC include:

• Karen Ferrante,
  Independent Director
• Arlene Morris,
  Independent Director
• Matthew Ros,
  Independent Director
• Stephanie Ascher,
  Investor Relations
• Peter Harwin,
  Director
• Chris Cain,
  Director
• Jessica Sachs,
  Chief Medical Officer
• John Green,
  Chief Financial Officer, Vice President - Finance, Controller
• Andrew Robbins,
  President, Chief Executive Officer and Principal Executive Officer, Director
• Llc Fmr,
  
• Bruce Booth,
  Director
• Funds Management Llc Fairmount,
  10% owner
• Ltd Fil,
  
• Venture Fund Ix, L.P.Atlas ...,
  
• Liam Ratcliffe,
  Director
• Jorn Aldag,
  Director
• Robert J Perez,
  Director
• Seth Ettenberg,
  Chief Scientific Officer
• Geoffrey Hodge,
  Chief Technical Officer
• Charles Wilson,
  Chief Executive Officer
• Michael Vasconcelles,
  Chief Medical Officer
• Matthew Scott Osborne,
  Chief Financial Officer
• Healthcare Capital Partners...,